Key result
Bivalirudin is a bivalent thrombin inhibitor approved for use in percutaneous transluminal coronary angioplasty, offering pharmacological advantages over hirudin such as enzymic metabolism and low immunogenicity.
Bivalirudin is a bivalent thrombin inhibitor with pharmacological advantages over hirudin, approved for PTCA and under investigation for cardiac surgery and HIT.
Answers are grounded in this paper and cite their sources.
Supports consideration for PTCA; leaves open expanded roles in surgery and HIT pending trials.
Bivalirudin (Angiomax) is a thrombin-inhibiting oligopeptide that was developed via rational drug design as a hirudin analogue ('hirulog'). Similar to hirudin, it is a bivalent thrombin inhibitor, as its 20-amino acid structure combines a carboxy-terminal region that recognises thrombin's fibrin(ogen)-binding site, and an amino-terminal tetrapeptide that inhibits the active site of thrombin, connected by a tetraglycine spacer. It has certain pharmacological advantages over hirudin, including enzymic metabolism (less dependence on renal clearance) and low immunogenicity (reduced potential for anaphylaxis). Bivalirudin is approved for use in percutaneous transluminal coronary angioplasty (PTCA), and is undergoing active investigation for anticoagulation during cardiac surgery, both 'off-pump' and with cardiopulmonary bypass ('on-pump'). Anecdotal 'off-label' experience for the treatment of heparin-induced thrombocytopenia shows promise.
No takes yet. Share an insight, caveat, or question.
Warkentin et al. (2005) conducted a review in Percutaneous transluminal coronary angioplasty (PTCA), cardiac surgery, heparin-induced thrombocytopenia. Bivalirudin (Angiomax) was evaluated. Bivalirudin is a bivalent thrombin inhibitor approved for use in percutaneous transluminal coronary angioplasty, offering pharmacological advantages over hirudin such as enzymic metabolism and low immunogenicity.
Synapse has enriched 10 related papers. Consider them for comparative context: